Trial Profile
An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GR37547 Ciprofloxacin 500 mg Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Participants Under Fasting Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ciprofloxacin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 14 Sep 2017 Status changed from recruiting to completed.
- 14 Aug 2017 Planned primary completion date changed from 3 Aug 2017 to 25 Aug 2017.
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.